PURPOSE: Innate immunity appears to play a key role in age-related macular degeneration (AMD). Although two previous studies reported that gene variations in Toll-like receptor (TLR)-3 and -4 are associated with AMD, other studies have not confirmed these associations. In this study, three independent samples (two U.S. clinic-based case-control study samples and one Australian population-based study sample) were used to further assess the association of the polymorphisms rs3775291 in TLR3 and rs4986790 in TLR4 with AMD. METHODS: AMD cases and unrelated controls were collected from the National Eye Institute Clinical Center (NEI, n = 320), the Age-Related Eye Disease Study (AREDS, n = 483), and the Blue Mountains Eye Study (BMES, n = 852). DNA extracted from subjects was genotyped for rs3775291 and rs4986790, and the associations with AMD were investigated. RESULTS: Neither of the two polymorphisms rs3775291 and rs4986790 had a statistically significant association with AMD in any of the three sample sets or in combinations of the sets. Analysis of the combined geographic atrophy or neovascular AMD cases in the NEI, AREDS, and BMES sample sets also failed to demonstrate statistically significant associations of those two single nucleotide polymorphisms with advanced AMD. CONCLUSIONS: Even with previously verified samples sets and adequate study powers, the results did not confirm the reported associations of TLR3 rs3775291 and TLR4 rs4986790 with AMD in the three independent samples, individually or combined.
PURPOSE: Innate immunity appears to play a key role in age-related macular degeneration (AMD). Although two previous studies reported that gene variations in Toll-like receptor (TLR)-3 and -4 are associated with AMD, other studies have not confirmed these associations. In this study, three independent samples (two U.S. clinic-based case-control study samples and one Australian population-based study sample) were used to further assess the association of the polymorphisms rs3775291 in TLR3 and rs4986790 in TLR4 with AMD. METHODS:AMD cases and unrelated controls were collected from the National Eye Institute Clinical Center (NEI, n = 320), the Age-Related Eye Disease Study (AREDS, n = 483), and the Blue Mountains Eye Study (BMES, n = 852). DNA extracted from subjects was genotyped for rs3775291 and rs4986790, and the associations with AMD were investigated. RESULTS: Neither of the two polymorphisms rs3775291 and rs4986790 had a statistically significant association with AMD in any of the three sample sets or in combinations of the sets. Analysis of the combined geographic atrophy or neovascular AMD cases in the NEI, AREDS, and BMES sample sets also failed to demonstrate statistically significant associations of those two single nucleotide polymorphisms with advanced AMD. CONCLUSIONS: Even with previously verified samples sets and adequate study powers, the results did not confirm the reported associations of TLR3rs3775291 and TLR4rs4986790 with AMD in the three independent samples, individually or combined.
Authors: Robert J Ross; Christine M Bojanowski; Jie Jin Wang; Emily Y Chew; Elena Rochtchina; Frederick L Ferris; Paul Mitchell; Chi-Chao Chan; Jingsheng Tuo Journal: Invest Ophthalmol Vis Sci Date: 2007-03 Impact factor: 4.799
Authors: Albert O Edwards; Dequan Chen; Brooke L Fridley; Katherine M James; Yanhong Wu; Goncalo Abecasis; Anand Swaroop; Mohammad Othman; Kari Branham; Sudha K Iyengar; Theru A Sivakumaran; Ronald Klein; Barbara E K Klein; Nirubol Tosakulwong Journal: Invest Ophthalmol Vis Sci Date: 2008-04 Impact factor: 4.799
Authors: Lin Liu; Istvan Botos; Yan Wang; Joshua N Leonard; Joseph Shiloach; David M Segal; David R Davies Journal: Science Date: 2008-04-18 Impact factor: 47.728
Authors: Christine Skerka; Nadine Lauer; Andreas A W A Weinberger; Claudia N Keilhauer; Jürgen Sühnel; Richard Smith; Ursula Schlötzer-Schrehardt; Lars Fritsche; Stefan Heinen; Andrea Hartmann; Bernhard H F Weber; Peter F Zipfel Journal: Mol Immunol Date: 2007-03-30 Impact factor: 4.407
Authors: Dominiek D G Despriet; Arthur A B Bergen; Joanna E Merriam; Jana Zernant; Gaetano R Barile; R Theodore Smith; Irene A Barbazetto; Simone van Soest; Arne Bakker; Paulus T V M de Jong; Rando Allikmets; Caroline C W Klaver Journal: Invest Ophthalmol Vis Sci Date: 2008-01 Impact factor: 4.799
Authors: Jingsheng Tuo; Robert J Ross; George F Reed; Qing Yan; Jie Jin Wang; Christine M Bojanowski; Emily Y Chew; Xiao Feng; Timothy W Olsen; Frederick L Ferris; Paul Mitchell; Chi-Chao Chan Journal: Ophthalmology Date: 2008-08-21 Impact factor: 12.079
Authors: Zhenglin Yang; Charity Stratton; Peter J Francis; Mark E Kleinman; Perciliz L Tan; Daniel Gibbs; Zongzhong Tong; Haoyu Chen; Ryan Constantine; Xian Yang; Yuhong Chen; Jiexi Zeng; Lisa Davey; Xiang Ma; Vincent S Hau; Chi Wang; Jennifer Harmon; Jeanette Buehler; Erik Pearson; Shrena Patel; Yuuki Kaminoh; Scott Watkins; Ling Luo; Norman A Zabriskie; Paul S Bernstein; Wongil Cho; Andrea Schwager; David R Hinton; Michael L Klein; Sara C Hamon; Emily Simmons; Beifeng Yu; Betsy Campochiaro; Janet S Sunness; Peter Campochiaro; Lynn Jorde; Giovanni Parmigiani; Donald J Zack; Nicholas Katsanis; Jayakrishna Ambati; Kang Zhang Journal: N Engl J Med Date: 2008-08-27 Impact factor: 91.245
Authors: Alexandra C Silveira; Margaux A Morrison; Fei Ji; Haiyan Xu; James B Reinecke; Scott M Adams; Trevor M Arneberg; Maria Janssian; Joo-Eun Lee; Yang Yuan; Debra A Schaumberg; Maria G Kotoula; Evangeline E Tsironi; Aristoteles N Tsiloulis; Dimitrios Z Chatzoulis; Joan W Miller; Ivana K Kim; Gregory S Hageman; Lindsay A Farrer; Neena B Haider; Margaret M DeAngelis Journal: Vision Res Date: 2009-09-26 Impact factor: 1.886